1 / 8

Published more than 185 peer-reviewed articles and more than 300 other texts or chapters in books

Eric Van Cutsem Head, Digestive Oncology, University Hospital Gasthuisberg and Professor of Internal Medicine, University of Leuven, Belgium. Published more than 185 peer-reviewed articles and more than 300 other texts or chapters in books On editorial board of many international journals

mignon
Télécharger la présentation

Published more than 185 peer-reviewed articles and more than 300 other texts or chapters in books

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Eric Van CutsemHead, Digestive Oncology, University Hospital Gasthuisberg and Professor of Internal Medicine, University of Leuven, Belgium • Published more than 185 peer-reviewed articles and more than 300 other texts or chapters in books • On editorial board of many international journals • Chairman of the EORTC GI group • Member of the general assembly of PanEuropean Trials on Adjuvant Colon Cancer • Chairs the ministerial commission on colon cancer prevention in Flanders • Vice-president of the International Digestive Cancer Alliance • Member of the ASCO Cancer Education Committee University Hospital Gasthuisberg

  2. Challenges for the treatment of colorectal cancer andgastric cancer Eric Van Cutsem University Hospital GasthuisbergLeuven, Belgium

  3. 09.00 Chair’s openingEric Van Cutsem 09.10 Forging a new standard in metastatic CRCEric Van Cutsem 09.40 Mounting evidence in early CRCAxel Grothey 10.10 Capecitabine: the new standard chemotherapy in advanced gastric cancer?Werner Scheithauer 10.40 Discussion 11.00 Coffee break Friday 8 February 2008Agenda

  4. Digestive system cancer: estimated new cases and deaths in the USA 150,000 125,000 100,000 75,000 50,000 25,000 0 Incidence Mortality Estimated new cases/ deaths in the USA (per year) Small intestine Colon Liver Pancreas Stomach American Cancer Society: cancer facts and figures 2007

  5. CRC: what are the challenges that we face in the next decade? • Feasibility of metastasectomy and optimal management of wound-healing/bleeding events • Establish optimal treatment duration for novel therapies • Determine optimal combination partners • Dose modifications for novel therapies and the impact on clinical outcomes • Determine whether novel therapies can replace 5-FU as the backbone for CRC therapy CRC = colorectal cancer; 5-FU = 5-fluorouracil

  6. Gastric cancer: ‘classical’ chemotherapy regimens provide limited benefit 10 8 6 4 2 0 Outcomes with cisplatin/5-FU or cisplatin/5-FU/epirubicin regimens 7–10 months Months 4–5 months Overall survival Time to progression Rivera F, et al. Cancer Treat Rev 2007;33:315–24

  7. No global ‘standard of care’ in metastatic gastric cancer • Surgery only curative option • 50% patients present with unresectable disease • Addition of docetaxel to cisplatin/5-FU improves survival1,2 • however, safety issues limit the use of the docetaxel/cisplatin/5-FU regimen in daily practice • Still unmet need in metastatic gastric cancer Ajani JA, et al. J Clin Oncol 2007;18:4001–3 Van Cutsem E, et al. J Clin Oncol 2006;24:4991–7

  8. Gastric cancer: what are the challenges that we face in the next decade? • Determine optimal combination regimens • Establish a backbone chemotherapy • Continue to evaluate novel treatment options • Determine whether novel therapies can improve survival and enhance quality of life • Extend treatment to a wider range of patients

More Related